Praxis Precision Medicines, Inc.(PRAX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PRAX Praxis Precision Medicines, Inc.

盘前交易 02-12 05:28:02 EST

323.29

+2.81

+0.88%

最高324.79	最低302.00	成交量46.34万
今开321.83	昨收320.48	日振幅7.11%
总市值88.60亿	流通市值74.11亿	总股本2,741万
成交额1.46亿	换手率2.02%	流通股本2,292万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PRAX","market":"US","secType":"STK","nameCN":"Praxis Precision Medicines, Inc.","latestPrice":323.29,"timestamp":1770843600000,"preClose":320.48,"halted":0,"volume":463371,"delay":0,"changeRate":0.008768097853220176,"floatShares":22922500,"shares":27407100,"eps":-12.922727,"marketStatus":"盘前交易","change":2.81,"latestTime":"02-12 05:28:02 EST","open":321.83,"high":324.79,"low":302,"amount":145764598.69788,"amplitude":0.071112,"askPrice":324.3,"askSize":10,"bidPrice":269.52,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-12.922727,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770906600000},"marketStatusCode":1,"adr":0,"listingDate":1602820800000,"exchange":"NASDAQ","adjPreClose":323.29,"postHourTrading":{"tag":"盘后","latestPrice":323.29,"preClose":323.29,"latestTime":"17:49 EST","volume":1813,"amount":586126.85,"timestamp":1770850155545,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.011326959506124,"impliedVol":0.8989,"impliedVolPercentile":0.472},"requestUrl":"/m/hq/s/PRAX/tweets","defaultTab":"tweets","newsList":[{"id":"1105033186","title":"财报前瞻｜Praxis Precision Medicines, Inc.本季度营收预计大幅下滑，机构观点待明朗","url":"https://stock-news.laohu8.com/highlight/detail?id=1105033186","media":"财报Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105033186?lang=zh_cn&edition=full","pubTime":"2026-02-12 10:44","pubTimestamp":1770864278,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines, Inc.将于2026年02月19日发布最新财报，市场关注其本季度营收与利润拐点的可见性以及研发推进节奏对亏损收窄的影响。由于当前缺乏披露毛利率与净利率的预测口径，相关指标暂无一致预估。上一财季管理层未提供可量化的本季度营收、毛利率、净利润或净利率、调整后每股收益等预测口径。基于公开渠道收集的区间内观点，机构对Praxis Precision Medicines, Inc.的态度以审慎偏中性为主，尚未形成明确的一边倒看多或看空共识。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜Praxis Precision Medicines, Inc.本季度营收预计大幅下滑，机构观点待明朗","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX"],"gpt_icon":0},{"id":"1157558681","title":"富国银行首次覆盖Praxis Precision Medicines 给予持股观望评级 目标价282美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1157558681","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157558681?lang=zh_cn&edition=full","pubTime":"2026-02-02 20:36","pubTimestamp":1770035783,"startTime":"0","endTime":"0","summary":"富国银行发布最新研报，宣布对精准医疗公司Praxis Precision Medicines, Inc. (PRAX) 启动覆盖研究。该机构给予该公司\"持股观望\"评级，同时设定目标股价为每股282美元。\n此次覆盖标志着华尔街对这家生物技术企业的关注度提升。分析师在报告中指出，虽然公司在新药研发领域展现潜力，但当前估值已基本反映其成长前景，因此建议投资者保持谨慎乐观态度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","IE00BJJMRZ35.SGD","LU0320765992.SGD","LU0109394709.USD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","PRAX","BK4139","LU0889565916.HKD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","IE0009355771.USD"],"gpt_icon":0},{"id":"1128938615","title":"Praxis Precision Medicines任命全球癫痫领域权威Orrin Devinsky博士担任临床战略负责人","url":"https://stock-news.laohu8.com/highlight/detail?id=1128938615","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128938615?lang=zh_cn&edition=full","pubTime":"2026-01-14 05:31","pubTimestamp":1768339876,"startTime":"0","endTime":"0","summary":"精准医疗公司Praxis Precision Medicines, Inc.宣布一项重要人事任命：全球癫痫治疗领域的顶尖专家Orrin Devinsky博士正式加入公司，出任临床战略负责人。这一战略布局彰显了Praxis深耕神经系统疾病治疗领域的决心。此次任命被视为Praxis加速推进其神经科学管线的重要里程碑。公司表示，Devinsky博士的专业洞察将直接应用于核心项目的临床开发路径优化，助力提升临床试验效率与成功率。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","PRAX","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","IE0009355771.USD","IE0002141913.USD","LU0109394709.USD","BK4139","LU0320765992.SGD","LU0889565916.HKD"],"gpt_icon":0},{"id":"1178329341","title":"Praxis Precision Medicines公司预计2026年2月中旬前提交两款新药申请：Ulixacaltamide用于特发性震颤及Relutrigine用于SCN2A/8A相关疾病","url":"https://stock-news.laohu8.com/highlight/detail?id=1178329341","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178329341?lang=zh_cn&edition=full","pubTime":"2026-01-12 21:08","pubTimestamp":1768223296,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines公司宣布，针对其在研药物Ulixacaltamide与Relutrigine的两项新药申请（NDA），预计将于2026年2月中旬前提交。其中，Ulixacaltamide的适应症为特发性震颤，而Relutrigine则旨在治疗与SCN2A及SCN8A基因相关的疾病。这一进展标志着公司在推进其精准医疗管线方面迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","LU0109394709.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","BK4139","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","PRAX","LU0320765992.SGD","LU0889565916.HKD","IE0009355771.USD","IE0002141913.USD"],"gpt_icon":0},{"id":"1105658123","title":"Praxis Precision Medicines宣布将在2026年初提交Relutrigine针对SCN2A和SCN8A发育性及癫痫脑病的NDA申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1105658123","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105658123?lang=zh_cn&edition=full","pubTime":"2025-12-11 21:01","pubTimestamp":1765458098,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines宣布将在2026年初提交Relutrigine针对SCN2A和SCN8A发育性及癫痫脑病的NDA申请。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU0320765992.SGD","BK4139","PRAX","LU0109394709.USD"],"gpt_icon":0},{"id":"1108126706","title":"Praxis Precision Medicines, Inc.：Embrave研究（A部分，N=9）的主要结果预计将在2026年上半年发布","url":"https://stock-news.laohu8.com/highlight/detail?id=1108126706","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108126706?lang=zh_cn&edition=full","pubTime":"2025-12-10 05:03","pubTimestamp":1765314199,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines, Inc.：Embrave研究（A部分，N=9）的主要结果预计将在2026年上半年发布","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK4139","PRAX","LU0320765992.SGD","LU0889565916.HKD"],"gpt_icon":0},{"id":"1156451905","title":"Praxis Precision Medicines宣布与FDA达成一致，对Elsunersen在早发Scn2a发育性及癫痫性脑病的注册路径进行简化与加速","url":"https://stock-news.laohu8.com/highlight/detail?id=1156451905","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156451905?lang=zh_cn&edition=full","pubTime":"2025-12-10 05:02","pubTimestamp":1765314150,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines宣布与FDA达成一致，对Elsunersen在早发Scn2a发育性及癫痫性脑病的注册路径进行简化与加速","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX","LU0109394709.USD","BK4139","LU0320765992.SGD","LU0889565916.HKD"],"gpt_icon":0},{"id":"1196344993","title":"Praxis Precision Medicines, Inc.：FDA 同意对 Embrave3 试验设计进行拟议更改，成为单臂基线对照研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1196344993","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196344993?lang=zh_cn&edition=full","pubTime":"2025-12-10 05:02","pubTimestamp":1765314132,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines, Inc.：FDA 同意对 Embrave3 试验设计进行拟议更改，成为单臂基线对照研究","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRAX","LU0320765992.SGD","LU0109394709.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"1180993297","title":"Praxis Precision Medicines, Inc.：单药疗法研究Power3计划于2026年上半年启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1180993297","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180993297?lang=zh_cn&edition=full","pubTime":"2025-12-09 05:47","pubTimestamp":1765230438,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines, Inc.：单药疗法研究Power3计划于2026年上半年启动","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX","LU0109394709.USD","LU0320765992.SGD","BK4139","LU0889565916.HKD"],"gpt_icon":0},{"id":"1130139994","title":"Praxis Precision Medicines公布Embold研究关于Relutrigine在Scn2a和Scn8a发育性及癫痫脑病中的积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1130139994","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130139994?lang=zh_cn&edition=full","pubTime":"2025-12-05 05:12","pubTimestamp":1764882729,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines公布Embold研究关于Relutrigine在Scn2a和Scn8a发育性及癫痫脑病中的积极结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU0109394709.USD","LU0320765992.SGD","PRAX","BK4139"],"gpt_icon":0},{"id":"1199927050","title":"Praxis Precision Medicines与FDA召开积极的NDA前会议，讨论Ulixacaltamide在特发性震颤中的应用","url":"https://stock-news.laohu8.com/highlight/detail?id=1199927050","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199927050?lang=zh_cn&edition=full","pubTime":"2025-12-05 05:02","pubTimestamp":1764882151,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines与FDA召开积极的NDA前会议，讨论Ulixacaltamide在特发性震颤中的应用","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK4139","LU0889565916.HKD","PRAX","LU0320765992.SGD"],"gpt_icon":0},{"id":"1166387197","title":"Praxis Precision Medicines：加速推进Relutrigine在Scn2a和Scn8a Dee患者中的开发计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1166387197","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166387197?lang=zh_cn&edition=full","pubTime":"2025-11-05 21:01","pubTimestamp":1762347693,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines：加速推进Relutrigine在Scn2a和Scn8a Dee患者中的开发计划","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX","BK4139"],"gpt_icon":0},{"id":"1116109522","title":"Praxis Precision Medicines 发布公司更新及2025年第三季度财务业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1116109522","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116109522?lang=zh_cn&edition=full","pubTime":"2025-11-05 21:01","pubTimestamp":1762347691,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines 发布公司更新及2025年第三季度财务业绩","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX","BK4139"],"gpt_icon":0},{"id":"1158510697","title":"Praxis宣布在Scn2a和Scn8a Dee患者中推进Relutrigine的加速开发计划，获得FDA积极反馈","url":"https://stock-news.laohu8.com/highlight/detail?id=1158510697","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158510697?lang=zh_cn&edition=full","pubTime":"2025-11-04 21:01","pubTimestamp":1762261279,"startTime":"0","endTime":"0","summary":"Praxis宣布在Scn2a和Scn8a Dee患者中推进Relutrigine的加速开发计划，获得FDA积极反馈","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRAX"],"gpt_icon":0},{"id":"1106249696","title":"异动解读 | Praxis Precision Medicines股价盘中大涨9.97%，新药临床试验成功推动股价持续攀升","url":"https://stock-news.laohu8.com/highlight/detail?id=1106249696","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106249696?lang=zh_cn&edition=full","pubTime":"2025-10-17 21:32","pubTimestamp":1760707948,"startTime":"0","endTime":"0","summary":"生物制药公司Praxis Precision Medicines周五盘中大涨9.97%，延续了前一交易日的强劲涨势。这一显著涨幅主要源于该公司实验性药物在临床试验中取得突破性进展，以及随后宣布的大规模融资计划。Praxis Precision Medicines本周早些时候宣布，其用于治疗本质性震颤的实验性药物ulixacaltamide在两项关键性三期临床试验中均达到了预定的主要终点。紧随临床试验成功之后，Praxis宣布了一项5.25亿美元的公开募股计划。Praxis Precision Medicines股价的持续上涨反映了投资者对公司未来发展前景的乐观预期。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"7fa23516ca85b1156f2152e8f7e5531d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PRAX"],"gpt_icon":0},{"id":"1152445060","title":"异动解读 | Praxis Precision Medicines盘前大涨5.71%，新药临床试验获重大突破","url":"https://stock-news.laohu8.com/highlight/detail?id=1152445060","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152445060?lang=zh_cn&edition=full","pubTime":"2025-10-17 16:52","pubTimestamp":1760691155,"startTime":"0","endTime":"0","summary":"生物制药公司Praxis Precision Medicines今日盘前大涨5.71%，延续了前一交易日的强劲涨势。这一显著涨幅主要源于公司宣布其用于治疗运动障碍的实验性药物ulixacaltamide在两项关键性三期临床试验中取得突破性进展。这一突破性进展对Praxis Precision Medicines具有重要意义，因为目前市场上尚无获批的专门针对本质性震颤的治疗方法。此外，Praxis还宣布计划发行新股，以利用其飙升的股价进行融资。这一系列利好消息推动了公司股价的持续上涨，反映了市场对Praxis Precision Medicines未来发展前景的乐观预期。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PRAX"],"gpt_icon":1},{"id":"1167533692","title":"异动解读 | Praxis Precision Medicines夜盘大涨7.97%，新药临床试验取得突破性进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1167533692","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167533692?lang=zh_cn&edition=full","pubTime":"2025-10-17 08:40","pubTimestamp":1760661628,"startTime":"0","endTime":"0","summary":"10月16日晚间，生物制药公司Praxis Precision Medicines股价大涨7.97%，延续了日间交易中的强劲涨势。这一显著涨幅主要源于该公司宣布其用于治疗运动障碍的实验性药物ulixacaltamide在两项关键性三期临床试验中取得突破性进展。这一突破性进展对Praxis Precision Medicines具有重要意义，因为目前市场上尚无获批的专门针对本质性震颤的治疗方法。这一系列利好消息推动了公司股价在日间和夜间交易中的持续上涨，反映了市场对Praxis Precision Medicines未来发展前景的乐观预期。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PRAX"],"gpt_icon":1},{"id":"2576772599","title":"Uniqure N.V.盘中异动 临近收盘股价大跌5.01%报59.69美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2576772599","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576772599?lang=zh_cn&edition=full","pubTime":"2025-10-17 03:33","pubTimestamp":1760643232,"startTime":"0","endTime":"0","summary":"北京时间2025年10月17日03时33分，Uniqure N.V.股票出现异动，股价大幅下跌5.01%。截至发稿，该股报59.69美元/股，成交量187.013万股，换手率3.04%，振幅8.48%。Uniqure N.V.股票所在的生物技术行业中，整体涨幅为0.36%。Uniqure N.V.公司简介：uniQure NV 是一家基因治疗公司。该公司专注于与 Bristol Myers Squibb 合作开发用于心血管疾病的基因疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101703335297325a88&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101703335297325a88&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["QURE","LU0889565916.HKD","LU0109394709.USD","LU0320765992.SGD","BK4139","PRAX"],"gpt_icon":0},{"id":"2575740532","title":"美股异动 | 特发性震颤药物研究出现积极进展 Praxis Precision Medicines(PRAX.US)飙升240%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575740532","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575740532?lang=zh_cn&edition=full","pubTime":"2025-10-16 22:31","pubTimestamp":1760625068,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周四，Praxis Precision Medicines早盘飙升240%，创三年新高，报194.90美元。消息面上，该公司宣布特发性震颤药物Ulixacaltamide在两项关键III期研究中达到主要终点：Study 1显示第8周Modified ADL-11评分改善4.3分p<0.0001，所有关键次要终点均具统计学显著性;Study 2显示维持效果显著p=0.0369，且第一个关键次要终点具统计学显著性p=0.0042。Ulixacaltamide安全性数据良好，两项研究中未出现药物相关严重不良事件，耐受性与既往试验一致。公司向FDA提交了Ulixacaltamide的新药预申请pre-NDA会议请求，推进药物审批进程。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1356123.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"美股异动 | 特发性震颤药物研究出现积极进展 Praxis Precision Medicines(PRAX.US)飙升240%","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PRAX","BK4139"],"gpt_icon":0},{"id":"2576565703","title":"万春医药盘中异动 股价大涨6.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2576565703","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576565703?lang=zh_cn&edition=full","pubTime":"2025-10-16 21:39","pubTimestamp":1760621942,"startTime":"0","endTime":"0","summary":"北京时间2025年10月16日21时39分，万春医药股票出现异动，股价快速上涨6.06%。截至发稿，该股报1.75美元/股，成交量203股，换手率0.00%，振幅1.75%。机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。万春医药股票所在的生物技术行业中，整体涨幅为0.65%。万春医药公司简介：BeyondSpring Inc从事临床阶段的生物制药活动，专注于癌症疗法的开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251016213902a6bd2214&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251016213902a6bd2214&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BYSI","PRAX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.praxismedicines.com","stockEarnings":[{"period":"1week","weight":0.0658},{"period":"1month","weight":0.1724},{"period":"3month","weight":0.8154},{"period":"6month","weight":5.8668},{"period":"1year","weight":2.8377},{"period":"ytd","weight":0.0969}],"compareEarnings":[{"period":"1week","weight":0.0084},{"period":"1month","weight":-0.0046},{"period":"3month","weight":0.0296},{"period":"6month","weight":0.0754},{"period":"1year","weight":0.1431},{"period":"ytd","weight":0.0147}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Praxis Precision Medicines, Inc.于2015年9月22日根据特拉华州法律成立。该公司是一家临床阶段的生物制药公司，将遗传见解转化为中枢神经系统（CNS）治疗方法的发展，CNS是以神经元失衡为特征的疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.298328},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.173694},{"month":3,"riseRate":0.2,"avgChangeRate":-0.183614},{"month":4,"riseRate":0.2,"avgChangeRate":-0.018417},{"month":5,"riseRate":0.4,"avgChangeRate":-0.124101},{"month":6,"riseRate":0.4,"avgChangeRate":-0.094382},{"month":7,"riseRate":0.6,"avgChangeRate":0.167978},{"month":8,"riseRate":0.4,"avgChangeRate":0.080633},{"month":9,"riseRate":0.6,"avgChangeRate":0.013557},{"month":10,"riseRate":0.6,"avgChangeRate":0.512334},{"month":11,"riseRate":0.666667,"avgChangeRate":0.073478},{"month":12,"riseRate":0.833333,"avgChangeRate":0.206625}],"exchange":"NASDAQ","name":"Praxis Precision Medicines, Inc.","nameEN":"Praxis Precision Medicines, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Praxis Precision Medicines, Inc.(PRAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Praxis Precision Medicines, Inc.(PRAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Praxis Precision Medicines, Inc.,PRAX,Praxis Precision Medicines, Inc.股票,Praxis Precision Medicines, Inc.股票老虎,Praxis Precision Medicines, Inc.股票老虎国际,Praxis Precision Medicines, Inc.行情,Praxis Precision Medicines, Inc.股票行情,Praxis Precision Medicines, Inc.股价,Praxis Precision Medicines, Inc.股市,Praxis Precision Medicines, Inc.股票价格,Praxis Precision Medicines, Inc.股票交易,Praxis Precision Medicines, Inc.股票购买,Praxis Precision Medicines, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Praxis Precision Medicines, Inc.(PRAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Praxis Precision Medicines, Inc.(PRAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}